Cell & Gene Meeting on the Mesa
The Cell & Gene Meeting on the Mesa is the leading annual conference for the cell and gene therapy industry. It brings together senior executives and decision-makers to advance research into cures. The event covers various topics including clinical trial design, payment models, and supply chain platforms. It features panels, partnering opportunities, networking, and presentations by top companies in the field. With over 2,000 attendees, including 20% C-level executives, the conference facilitates partnerships through one-on-one meetings and showcases clinical and commercial progress.
Date: October 17-9, 2024
Location: Arizona Biltmore, Phoenix, AZ
JOIN US!
Don’t miss the opportunity to meet with our industry-leading experts and gain invaluable insights into the latest advancements in cell and gene therapy manufacturing. Engage in one-on-one meetings with our experts to explore potential partnerships and discover innovative solutions for your business. Complete the form to schedule a meeting with Catalent Cell & Gene Therapy experts at the Cell & Gene Meeting on the Mesa!
FEATURED SPEAKING SESSIONS
Title: Science Slam: Conquering CMC Challenges – Are We There Yet?
Date: October 7, 2024
Time: 10:00-10:30 am EDT
Room: FLW Ballroom F
Chair: Rupa Pike
Title: Company Presentation
Date: October 7, 2024
Time: 3:30-3:45 pm EDT
Room: FLW Ballroom F
Speaker: Frederic Cedrone
SPEAKERS
Rupa Pike
Senior Director and Global Head of Strategic Alliances
Catalent
Frederic Cedrone, Ph.D.
Vice President
Corporate Innovation
Catalent
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.
